Douglas A. Roeder
Douglas A. Roeder's purchase track record
How the stock did after each of Douglas A. Roeder's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/19/2026 | SENS | $125K | pending | pending | — |
| 5/12/2026 | SENS | $126K | +36.6% | pending | — |
| 3/13/2026 | SENS | $100K | +27.3% | +54.4% | +15.4% |
| 11/7/2025 | SENS | $87K | +23.6% | -16.3% | +10.0% |
| 12/12/2024 | SENS | $136K | +31.6% | +20.6% | -0.1% |
| 8/30/2023 | SENS | $162K | +11.3% | +32.1% | +12.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating. Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.
Transaction History
| SENS | ▲ Buy | Open Market | 13,953 | $125K | 8/19/2026 | View on chart |
| SENS | ▲ Buy | Grant | 2,751 | $15K | 7/1/2026 | View on chart |
| SENS | ▲ Buy | Grant | 9,852 | $0 | 5/20/2026 | View on chart |
| SENS | ▲ Buy | Open Market | 22,686 | $126K | 5/12/2026 | View on chart |
| SENS | ▲ Buy | Grant | 2,218 | $15K | 4/1/2026 | View on chart |
| SENS | ▲ Buy | Open Market | 17,500 | $100K | 3/13/2026 | View on chart |
| SENS | ▲ Buy | Grant | 2,504 | $15K | 1/2/2026 | View on chart |
| SENS | ▲ Buy | Open Market | 15,000 | $87K | 11/7/2025 | View on chart |
| SENS | ▲ Buy | Grant | 35,714 | $15K | 10/1/2025 | View on chart |
| SENS | ▲ Buy | Grant | 30,987 | $15K | 7/1/2025 | View on chart |
| SENS | ▲ Buy | Grant | 111,386 | $0 | 5/23/2025 | View on chart |
| SENS | ▲ Buy | Grant | 22,183 | $15K | 4/1/2025 | View on chart |
| SENS | ▲ Buy | Grant | 31,183 | $15K | 1/2/2025 | View on chart |
| SENS | ▲ Buy | Open Market | 25,000 | $13K | 12/13/2024 | View on chart |
| SENS | ▲ Buy | Open Market | 300,000 | $123K | 12/12/2024 | View on chart |
| SENS | ▲ Buy | Grant | 43,755 | $15K | 10/1/2024 | View on chart |
| SENS | ▲ Buy | Grant | 236,344 | $0 | 5/22/2024 | View on chart |
| SENS | ▲ Buy | Open Market | 300,000 | $162K | 8/30/2023 | View on chart |
| SENS | ▲ Buy | Grant | 200,000 | $150K | 6/9/2023 | View on chart |
| SENS | ▲ Buy | Grant | 147,948 | $0 | 5/17/2023 | View on chart |
| SENS | ▲ Buy | Grant | 99,557 | $0 | 5/26/2022 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 2,205 | $0 | 5/18/2022 | View on chart |
| TNDM | ▼ Sell | Other | 11,568 | $0 | 10/15/2021 | View on chart |
| TNDM | ▼ Sell | Other | 11,568 | $0 | 10/15/2021 | View on chart |
| TNDM | ▼ Sell | Other | 1,000,000 | $0 | 10/15/2021 | View on chart |
| TNDM | ▼ Sell | Other | 3,766 | $0 | 10/15/2021 | View on chart |
| SENS | ▲ Buy | Option Exercise | 128,817 | $174K | 8/25/2021 | View on chart |
| SENS | ▲ Buy | Option Exercise | 86,930 | $171K | 8/25/2021 | View on chart |
| SENS | ▼ Sell | Open Market | 215,747 | $755K | 8/25/2021 | View on chart |
| SENS | ▼ Sell | Open Market | 125,342 | $457K | 8/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Beta Bionics and Senseonics announce iLet-Eversense 365 integration
Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.
Beta Bionics and Senseonics announce iLet-Eversense 365 integration. Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.